RxDoctor Payments Data

Sujatha Lingatlu, MD

Family Medicine · Suwanee, GANPI 1134135809

Payments from drug & device makers

$1,088in general payments, 2019–2025

Across 52 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$332
  • Novo Nordisk$136
  • Abbott$105
  • Exact Sciences$96
  • Medtronic$89
  • AstraZeneca$85
  • plus $245 from 9 others

What the payments were for

  • Food & beverage$1,088100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,088 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$52,425
Medicare patients
95
Services billed
1,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$69,721
JanuviaSitagliptin Phosphate37$60,984
OzempicSemaglutide40$59,735
EliquisApixaban27$30,324
JardianceEmpagliflozin23$29,932
FarxigaDapagliflozin Propanediol19$26,548
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$20,431
TrulicityDulaglutide15$15,510
TradjentaLinagliptin12$14,778
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$5,351
Rosuvastatin Calcium158$3,697
Nano 2nd Gen Pen NeedlePen Needle, Diabetic19$2,102
Levothyroxine Sodium233$2,026
Fentanyl13$1,617
Albuterol Sulfate HfaAlbuterol Sulfate66$1,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$332$85,23155 claims
MerckJanuvia$28$60,98437 claims
Novo NordiskOzempic$136$59,73540 claims
Boehringer IngelheimJardiance, Tradjenta$24$44,71035 claims
AstraZenecaFarxiga$85$26,54819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →